Want to jump right to here next time? Bookmark: www.canpku.org/education/treatments/hcu

HCU Treatments and Therapies in Canada

Classical Homocystinuria (HCU) is most commonly due to cystathionine beta-synthase (CBS) deficiency. Treatment is individualized and guided by a metabolic clinic. Management focuses on lowering homocysteine levels, supporting healthy growth and development, and reducing the risk of complications (including blood clots).

Page focus: This page focuses primarily on classical homocystinuria due to cystathionine beta-synthase (CBS) deficiency, which is the most commonly recognized form of HCU managed with medical nutrition therapy, vitamin therapy, and homocysteine-lowering treatment. Other causes of elevated homocysteine (such as certain cobalamin-related disorders or severe MTHFR variants) may require different management approaches. Your metabolic clinic can clarify which diagnosis applies to you.

Important: Treatment decisions depend on HCU type (including whether a person is B6-responsive), age, biochemical stability, clinical history (including clot risk), and ongoing lab monitoring. Always follow your metabolic clinic's recommendations.

Canada check: Drug availability and coverage can vary by province/plan. Your clinic can confirm what applies to your HCU type and situation. You can also verify authorized/marketed drugs using the Health Canada Drug Product Database (DPD): Search the DPD.

Core treatment approaches

For many individuals with HCU, treatment may include medical nutrition therapy, vitamin/cofactor therapy (when appropriate), a homocysteine-lowering medication (betaine), and long-term monitoring. Your clinic will individualize targets and treatment goals.

Dietary management and medical nutrition

In pyridoxine (vitamin B6) non-responsive HCU, a methionine-restricted diet may be recommended. This often includes specialized metabolic formula and careful planning to meet nutrition needs while controlling methionine intake. Diet targets vary by age, growth, and lab monitoring.

Related education: Nourish | Low Protein Meal Planning Tools

Vitamin therapy (B6 responsiveness) and supportive vitamins

Some individuals have pyridoxine-responsive HCU. In these cases, pyridoxine (vitamin B6) may reduce homocysteine levels and improve biochemical control (dose and monitoring are clinic-directed).

Your clinic may also recommend folic acid (folate) and vitamin B12 (cobalamin) as part of a complete management plan, depending on labs and individual needs.

Tip: Do not start or change high-dose vitamins without clinic guidance. Dosing varies and should be monitored.

Homocysteine-lowering medication: betaine

Betaine (medical name: betaine anhydrous) can be used to help lower homocysteine levels. It may be used alongside diet and/or vitamin therapy, depending on the person's HCU type and lab results.

Brand example: CYSTADANE® (betaine anhydrous) is a recognized product used for homocystinuria management. Your clinic can advise whether this is appropriate and how coverage works where you live.

Note: Betaine therapy requires clinic monitoring. Some people may develop elevated methionine levels on betaine, so labs and targets should be clinic-directed.

Ongoing monitoring and long-term care

Clinics use laboratory monitoring (including homocysteine and related markers) to assess biochemical control and adjust treatment. Eye health, bone health, growth, development, and overall wellbeing are monitored across life stages.

Transition to adult care and pregnancy planning should be coordinated with metabolic and specialist teams.

Hospital care and special situations

Emergency planning still matters even when day-to-day management is stable. In classical HCU, urgent care may focus less on acute metabolic decompensation than in some other IEMs, and more on complications such as thrombosis risk, severe illness, surgery planning, hydration and nutrition support, and communication with metabolic specialists.

Reducing Clot Risk

A major medical concern in HCU is thromboembolism (blood clots). Good biochemical control is one part of risk reduction, but individual risk varies. Your healthcare team may discuss additional planning for higher-risk situations such as surgery, immobility, pregnancy/postpartum, or a prior history of clots.

Tip: Ask your clinic what warning signs matter most for your family and what to do if symptoms occur.

Emergency Preparedness

Even when day-to-day management is stable, emergency planning matters. Families and adults should keep an updated emergency letter and know which hospital to attend in urgent situations.

For practical planning support, families may find our emergency preparation resource helpful:

Emergency Preparedness Toolkit (HCU and related disorders)

This toolkit supports conversations with your clinic and local hospital. Always individualize emergency planning with your care team. We thank HCU Network America for their support in sharing this resource.

In hospital settings, care may focus on urgent evaluation and treatment of complications (for example, suspected blood clots), support during surgery or severe illness, hydration and nutrition planning, and coordination with metabolic specialists. If anticoagulation or other acute treatments are needed, they are directed by the hospital team based on the individual situation.

Therapy snapshots by type

This page keeps the main focus on classical HCU due to CBS deficiency, but the dropdowns below also note other homocysteine disorders because families may hear similar terms used in clinic or online.

Classical HCU due to CBS deficiency

Main treatment goals: lower homocysteine, maintain safe methionine control, support healthy growth and development, and reduce complication risk
Common treatment components: methionine-restricted diet, metabolic formula, pyridoxine trial if appropriate, folate/B12 support when indicated, and betaine
Monitoring priorities: total homocysteine, methionine, nutrition status, eye health, bone health, and clot risk planning

Pyridoxine-responsive classical HCU

Main feature: some people respond biochemically to pyridoxine (vitamin B6)
What treatment may include: clinic-directed B6 therapy, sometimes with folate, B12, betaine, and diet adjustments depending on control
Important note: responsiveness must be determined by the clinic and does not remove the need for monitoring

Pyridoxine non-responsive or partially responsive classical HCU

Main feature: diet and medical nutrition usually play a larger role
What treatment may include: methionine restriction, specialized formula, betaine, and supportive vitamins depending on labs
Important note: betaine can lower homocysteine, but methionine still needs monitoring because levels can rise in some people

Other disorders with high homocysteine: cobalamin-related and remethylation disorders

Some disorders with high homocysteine are not classical CBS deficiency HCU. Examples include cobalamin-related remethylation disorders such as cblC and other intracellular cobalamin defects, as well as severe MTHFR deficiency. These conditions may require different therapy patterns, often including hydroxocobalamin, betaine, folate-related support, and other clinic-directed treatments rather than a classical CBS-only approach.

Medication list: Canada and worldwide context

Not every medication applies to every kind of homocystinuria. The list below keeps CBS deficiency first, while also noting therapies families may hear about for related conditions.

Core medications and supportive therapies used for classical CBS deficiency

CYSTADANE (betaine anhydrous)
Betaine is a recognized homocysteine-lowering therapy used in homocystinuria management. Health Canada lists CYSTADANE in the Drug Product Database, and the product monograph describes its use as an anti-homocysteine agent.

Pyridoxine (vitamin B6)
Used in pyridoxine-responsive classical HCU and sometimes assessed by a clinic-directed response trial. Dosing and follow-up are individualized.

Folate / folic acid and vitamin B12 support
These may be used as supportive therapies depending on labs, nutritional status, and the underlying diagnosis.

Therapies more associated with remethylation and cobalamin-related disorders

Hydroxocobalamin
Hydroxocobalamin is a key therapy families may hear about in cobalamin-related remethylation disorders such as cblC. It is not the main therapy pattern for classical CBS deficiency, but it is highly relevant when the diagnosis is a cobalamin-related homocysteine disorder. Canadian hydroxocobalamin products exist, though specific products and routes may vary over time.

Betaine
Betaine may also be part of management in remethylation disorders, but the full treatment pattern differs from classical CBS deficiency.

Worldwide and research context

Families may see other formulations, hospital practices, or research approaches discussed internationally. These can differ by country and diagnosis. For newer or study-based treatments, the best place to track them is the HCU Studies and Trials page rather than the main treatments page.

By province: reimbursement and access snapshot

Public coverage rules can differ by program, age, diagnosis, product type, and province. Betaine, vitamins, metabolic formula, and low-protein foods may each follow different pathways.

British Columbia

Check BC PharmaCare and your clinic for the exact route used for betaine, formula, low-protein products, or supportive medications. Access may vary by product and plan type.

Ontario

Ontario access may involve the Ontario Drug Benefit Formulary, Exceptional Access Program, metabolic formula pathways, hospital supply, or private insurance depending on the therapy and diagnosis.

Alberta

Check Alberta's Interactive Drug Benefit List for the specific product. Some therapies may require special authorization, clinic documentation, or other non-standard access routes.

Manitoba

Check Manitoba's eFormulary and Pharmacare resources for betaine, formula, or other products. Coverage can differ between formulary listing, Pharmacare, and exception processes.

Quebec

Check RAMQ for current public coverage status. Depending on the plan, some people may also access medications or supplies through private insurance.

Nova Scotia and other Atlantic provinces

Atlantic public plans may use formulary and exception status processes. Clinic-supported documentation may be important for specialized metabolic products.

First Nations and Inuit clients

The federal Non-Insured Health Benefits drug benefit list may be relevant in addition to provincial processes. Your clinic and pharmacy can help determine whether NIHB, provincial coverage, or both apply.

Practical tip: If you are trying to access betaine, formula, low-protein foods, hydroxocobalamin, or supportive vitamins, ask your clinic which route applies in your province: formulary listing, limited use, Exceptional Access, Special Authority, case-by-case reimbursement, hospital supply, private insurance, NIHB, or clinic-supported supply. Things can change over time - if you note a change - please let us know so we can update this page.

Research, trials, and registries

Looking for research studies, registries, or clinical trials, including studies that may be recruiting? We track current research and study opportunities on our dedicated page:

HCU Studies & Trials HCU Registry

Optional external resources:

Sources and references

External links are shared for education and support. CanPKU+ does not control external content. Always confirm medical guidance and reimbursement details with your metabolic clinic.